Redback spider venom (LHV) (LHV)

Redback spider venom, produced by the Australian spider Latrodectus hasselti, is a complex biochemical cocktail containing various proteins, the most potent of which is the 130 kDa neurotoxin alpha-latrotoxin (StatPearls, 2023). This toxin targets the presynaptic nerve terminals of vertebrates, where it binds to specific receptors such as latrophilin-1 and neurexin-1-alpha (UniProt, P0C2C6). Upon binding, it induces the formation of cation-selective pores in the presynaptic membrane, leading to a massive, uncontrolled release of neurotransmitters like acetylcholine and GABA (PubMed, 10448053). This physiological disruption results in latrodectism, a condition marked by severe regional pain, muscle tremors, and autonomic symptoms (NIH, 2022). The primary therapeutic intervention is Redback spider antivenom, which contains equine-derived antibodies that bind and neutralize the venom components (Toxinology, 2020). However, the clinical utility of the antivenom has been scrutinized in recent years due to trials suggesting limited efficacy in reducing pain compared to placebo (The Lancet, 2014).

Other names

Latrodectus hasselti venomRed-back spider venomAlpha-latrotoxin (major component)

The antivenom consists of equine-derived IgG antibodies that bind to and neutralize the venom components, specifically alpha-latrotoxin, thereby preventing the toxin from interacting with presynaptic receptors and inducing uncontrolled neurotransmitter release.